Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0EG1I
|
||||
| Former ID |
DNAP001690
|
||||
| Drug Name |
Tofacitinib
|
||||
| Synonyms |
Xeljanz (TN)
|
||||
| Drug Type |
Small molecular drug
|
||||
| Company |
Pfizer
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C16H20N6O
|
||||
| InChI |
InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m1/s1
|
||||
| InChIKey |
UJLAWZDWDVHWOW-YPMHNXCESA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
14898931, 16573063, 24203044, 50100095, 56468341, 56479518, 80408829, 93578178, 93578180, 99005545, 99436938, 99444654, 103506979, 104076339, 109693014, 118049771, 124757868, 124939204, 124939205, 125164719, 126617354, 126636329, 131541360, 134344290, 135253188, 135626691, 135697694, 135723912, 136367982, 137055230, 142909486, 143498234, 144115851, 152159600, 152239919, 152258788, 152344045, 160646103, 160647639, 160819105, 160969237, 162011739, 162133672, 162193956, 162766622, 164043529, 164194011, 164783370, 170482324, 170482440
|
||||
| ChEBI ID |
ChEBI:71200
|
||||
| SuperDrug ATC ID |
L04AA29
|
||||
| Target and Pathway | |||||
| Target(s) | Tyrosine-protein kinase JAK3 | Target Info | Modulator | [551871] | |
| References | |||||
| Ref 524789 | ClinicalTrials.gov (NCT02157012) Evaluation of the Condition of Rheumatoid Arthritis After Treatment. U.S. National Institutes of Health. | ||||
| Ref 541020 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5677). | ||||
| Ref 551871 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.